Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
Line Lundegaard BangLone Wulff MadsenRune Micha PedersenAnna Christine NilssonIsik Somuncu JohansenThomas Emil AndersenPublished in: Journal of infection and public health (2024)